New functionality will involve a best-in-class combination of generative AI and integrated data solutions to improve patient outcomes
Belfast and London, 21 March 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces a significant upgrade to its DXRX platform. This upgrade focuses on industry-leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health.
These upgrades aim to breakdown siloed datasets, provide greater depth and breadth of Diaceutics’ longitudinal insight of the patient journey, address healthcare inequalities and enable more patients to access appropriate therapies, solidifying Diaceutics’ position as a leader in healthcare data security and privacy.
Commenting on the upgrade, Jordan Clark, Chief Data Officer of Diaceutics said: “Our Practise Gaps Study identified that a staggering 64.4% of patients do not get the right treatment and todays platform upgrade will empower healthcare providers to make timely and accurate treatment decisions, ultimately benefiting more patients.”
Key Highlights of the DXRX Platform Update
Enhanced Data Security & Privacy
Diaceutics has successfully conducted its first pilot project using its newly established HIPAA-compliant, multi-modal real-world dataset. This is a significant step forward, enabling a comprehensive view of the patient journey while upholding the strictest data security and privacy standards. This innovative capability empowers life science companies with access to HIPAA-certified Real-World Data (RWD) within a week, eliminating the months previously required for stakeholder coordination to assemble disparate data sources.
Integrated Data Solutions: A Gold Standard for Reliable Insights
The DXRX platform upgrade goes beyond a technological advancement; it represents a strategic shift in healthcare data management. The multi-modal real-world dataset incorporates Diaceutics’ industry-leading lab data from over 500 US labs, alongside claims data, electronic health records (EHR), and social determinants of health (SDOH) data. These pre-certified and HIPAA-compliant datasets establish a new benchmark for reliability and compliance. This comprehensive resource grants life sciences organisations unparalleled access to critical issues like healthcare equity in clinical trial recruitment.
Enriching the Data Landscape with Social Detriments of Health
Healthcare inequality remains a major challenge for the life sciences industry, particularly in the realm of precision medicine. Recognising this challenge, Diaceutics has now integrated SDOH data into its HIPAA-certified multi-modal real-world dataset. This empowers life sciences organizations to develop strategies that promote more equitable healthcare. For instance, clinical trial enrolment can be expanded to consider not only biomarker status but also factors like ethnicity and race. This fosters more representative clinical trials while upholding patient privacy and enabling researchers to explore the connections between social factors and health outcomes.
A One-Stop Shop for Precision Medicine
Previously, accessing comprehensive healthcare data involved working with multiple vendors, a process fraught with complexities, delays and increased costs. Diaceutics streamlines this process by offering a unified solution within the DXRX platform. This strategic move positions Diaceutics as the single source for life sciences organisations seeking unparalleled depth and breadth of data for their precision medicine endeavours.
AI LLM: Unlocking Hidden Gems within Complex Data
The DXRX platform is further bolstered by the introduction of the Diaceutics Large Lab Model (DLLM). This proprietary AI tool, developed by Diaceutics’ team of data scientists and clinical experts, tackles complex and diverse datasets. The DLLM extracts valuable insights previously hidden within vast amounts of healthcare data. Beyond uncovering new knowledge, the DLLM accelerates the delivery of insights to life science organisations. This is particularly crucial for Signal products where the actionable nature and freshness of insights are paramount to business success.
Transforming the Healthcare Landscape
These groundbreaking advancements within DXRX solidify Diaceutics’ unwavering commitment to innovation and data excellence.
Jordan Clark, Chief Data Officer at Diaceutics commented:
This upgrade signifies a transformative leap in our journey, driven by our concerted data strategy investment announced earlier this year. The development of a multi-modal RWD that is HIPAA certified, coupled with expanded data sources and the growing use of AI (DLLM), signifies our commitment to innovation and data excellence, privacy and security.
Clark further emphasized the significance of these advancements, stating:
The future of personalized medicine has arrived, and Diaceutics is at its forefront, shaping a new era. Our strategic investment positions Diaceutics as a trailblazer in the precision medicine landscape, offering life sciences organisations not only cutting-edge but also secure, efficient, and seamlessly interconnected data platforms to revolutionise healthcare.
For media enquiries contact:
Cathy Magovern Tel: +44 (0)28 9040 6500
Corporate Marketing & Communications Director [email protected]
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®
